<DOC>
	<DOC>NCT00947245</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics following single oral and multiple oral doses BMS-791325 in healthy Japanese subjects.</brief_summary>
	<brief_title>Japanese Bridging Study Conducted in the United States</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy male and female subjects aged 20 to 49 years, with BMI of 1830 kg/m2 First generation Japanese. Subject born in Japan and has not lived outside of Japan for &gt; 10 years, and subject can trace maternal and paternal Japanese ancestry Any significant acute or chronic medical illness. Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control. Gastrointestinal disease that may impact the absorption of study drug or that required treatment with a protocon inhibitor, antacid or H2 blocker. History of eczema, psoriasis, or any intermittent or active dermatitis. Positive for HIV or HCV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>